Watching a loved one struggle with memory loss is one of the hardest things a family can go through. And if you have been noticing changes in your own thinking or memory, the uncertainty alone can feel overwhelming. You are not alone in that worry. An estimated 7.4 million Americans age 65 and older are living with Alzheimer’s dementia right now, according to the 2026 Alzheimer’s Disease Facts and Figures report.
For decades, confirming the biological signs of the disease typically required expensive brain scans or an invasive spinal tap. But that changed in 2025, when new blood tests for Alzheimer’s became available for the first time, giving families and patients a simpler path toward answers.
So, is there a blood test for Alzheimer’s? Yes. And the options are growing. Here is what you need to know about testing for Alzheimer’s, including blood-based tests, genetic testing for Alzheimer’s, and how to talk to your doctor about next steps.
Key Takeaways
- Two blood tests for Alzheimer’s received FDA clearance in 2025, offering a simpler alternative to brain scans and spinal taps
- The tests measure proteins in the blood linked to amyloid plaques and are available for adults 55 and older with signs of cognitive decline
- Alzheimer’s disease DNA testing (APOE gene testing) assesses genetic risk but cannot predict whether you will develop the disease
- A blood test result alone does not diagnose Alzheimer’s and must be interpreted by a doctor alongside other clinical information
How Alzheimer’s Was Tested Before Blood Tests
Understanding how doctors diagnosed Alzheimer’s in the past helps put the new options in context.
Traditional Diagnostic Methods
For years, how to test for Alzheimer’s meant going through a combination of steps:
- Cognitive assessments: Memory and thinking tests given by a doctor to check for changes beyond normal aging
- Brain imaging (PET scans): Specialized scans that can detect amyloid plaques in the brain, a hallmark of Alzheimer’s disease
- Spinal fluid analysis (lumbar puncture): A needle is inserted into the lower back to collect cerebrospinal fluid, which is then checked for proteins linked to Alzheimer’s
PET scans are expensive and not available everywhere. Spinal taps can be uncomfortable and stressful. Both require specialized equipment, making them hard to access in rural areas or smaller clinics.
According to the National Institute on Aging (NIA), a diagnosis also includes a review of medical history, family history, physical exams, and sometimes additional lab work to rule out other causes of memory problems.
Why a Simpler Option Was Needed
Many people showing early signs of cognitive decline never received proper evaluation because the existing tools were too costly, too invasive, or unavailable nearby.
What Is the Alzheimer’s Disease Blood Test?
In May 2025, the U.S. Food and Drug Administration (FDA) cleared the first blood test designed to help diagnose Alzheimer’s disease. A second test followed in October 2025. Both work through a simple blood draw at a lab or doctor’s office.
The Two FDA-Cleared Blood Tests
- Lumipulse (cleared May 2025): Measures a ratio of two proteins, pTau217 and beta-amyloid 1-42, in blood plasma. A higher ratio may indicate the presence of amyloid plaques in the brain. Cleared for adults 55 and older showing signs of cognitive decline. Clinical validation showed 91.7% positive concordance and 97.3% negative concordance with PET and CSF testing, according to published research.
- Elecsys pTau181 (cleared October 2025): Measures phosphorylated tau 181, another protein linked to Alzheimer’s pathology. Designed specifically for the primary care setting to help rule out patients who are unlikely to have Alzheimer’s-related amyloid pathology. Clinical studies showed a 97.9% negative predictive value in an early-stage population, according to a PMC-published review.
What the Blood Test Actually Measures
An Alzheimer’s disease blood test does not diagnose Alzheimer’s on its own. Instead, the test measures specific proteins in the blood that may signal the buildup of amyloid plaques in the brain. Amyloid plaques are clumps of misfolded protein that are considered one of the earliest biological signs of Alzheimer’s disease.
Your doctor then interprets the results alongside other information, including your medical history, cognitive tests, and family history, before reaching any conclusions.
Who Can Get the Blood Test?
Not everyone qualifies for the Alzheimer’s disease blood test right now.
Eligibility Requirements
According to the FDA, you may be eligible if you:
- Are 55 years of age or older
- Have been medically evaluated for signs of cognitive decline
- Have symptoms like memory loss, confusion, or difficulty with thinking that go beyond normal forgetfulness
A medical assessment typically includes an evaluation of your medical history and some form of cognitive testing. Forgetting where you put your keys once in a while is normal. But if forgetfulness starts affecting daily activities, that may warrant a closer look.
Where Can I Get a Blood Test for Alzheimer’s?
If you meet the eligibility criteria, your primary care doctor or a specialist (such as a neurologist) can order the test. You would go to a lab for a standard blood draw, and the sample would be sent to a centralized lab with the equipment to run the analysis.
As of now, insurance coverage for these tests is still evolving and may not be available everywhere. Ask your provider about cost and coverage options before scheduling.
What Happens After the Results
A blood test result is one piece of a larger puzzle.
Understanding the Score Range
Results typically fall into one of three ranges:
- High-end scores: May indicate a greater than 90% likelihood of amyloid plaques associated with Alzheimer’s, based on FDA clinical validation data
- Low-end scores: Suggest amyloid plaques are very unlikely
- Intermediate scores: About 20% of people fall in a middle range and may need additional testing, such as a PET scan or a referral to a neurologist
What a Positive Result Means
A positive result does not automatically mean you have Alzheimer’s disease. Doctors must weigh the blood test findings along with other clinical information, medications you take, and your family history before making any diagnosis.
If further evaluation is needed, your doctor may recommend seeing a neurologist or geriatric specialist to discuss whether newer medications designed to slow progression could be appropriate.
Alzheimer’s Disease DNA Testing and Genetic Risk
Blood tests and genetic tests are two different tools. While blood tests for Alzheimer’s look for proteins linked to the disease right now, Alzheimer’s disease DNA testing looks at your genes to assess future risk.
The Role of the APOE Gene
The most well-known gene connected to late-onset Alzheimer’s is the APOE gene, specifically the e4 variant (APOE4). According to the National Institute on Aging, about 25% of people carry one copy of APOE4. Carrying this variant does not mean you will develop Alzheimer’s. Most people with APOE4 never do.
Here is what Alzheimer’s genetic testing can and cannot tell you:
- Can tell you: Whether you carry the APOE4 gene variant, which may increase your lifetime risk
- Cannot tell you: Whether you will actually develop Alzheimer’s disease
A study highlighted by the NIH found that people with two copies of APOE4 (about 2-3% of the population) showed signs of Alzheimer’s pathology significantly earlier. Having one copy does raise risk, but most people with a single copy never develop the disease.
Should You Get Genetic Testing for Alzheimer’s?
Genetic testing for Alzheimer’s is a personal decision. The NIA Genetics Fact Sheet notes that genetic test results cannot fully predict who will or will not develop Alzheimer’s. A PMC-published study also found that results may affect your ability to obtain certain types of insurance, such as long-term care coverage. A genetic counselor can help you weigh the pros and cons before testing.
Why Early Detection Matters
Catching Alzheimer’s early will not reverse the disease, but it may open doors that would otherwise stay closed.
Benefits of Early Testing
- Access to newer medications: Several therapies designed to slow Alzheimer’s progression may be more effective when started early
- Better planning: Early awareness gives individuals and families time to plan for care, finances, and legal decisions
- Clinical trial participation: People diagnosed earlier may qualify for research studies testing promising new approaches
- Peace of mind: For many, a negative result brings significant relief
The 2025 Alzheimer’s Disease Facts and Figures report found that nearly 4 in 5 Americans said they would want to know if they had Alzheimer’s disease before symptoms began affecting daily life.
Conclusion
Blood tests for Alzheimer’s are a meaningful step forward in making early detection simpler and more accessible. Whether you are exploring a blood test, considering genetic testing for Alzheimer’s, or just trying to understand your options, talking with a qualified healthcare provider is the best place to start.
At Rocky Mountain Regenerative Medicine (RMRM), we focus on personalized, data-driven care that puts your long-term health first. Our biomarker testing programs, hormone optimization, peptide therapy, and hyperbaric oxygen therapy support brain health and overall vitality as part of a longevity-focused care plan.
Book an appointment to discuss how proactive diagnostics can support your health goals.
Note: The information in this article is for educational purposes only and is not intended as medical advice. Alzheimer’s disease diagnosis requires evaluation by a qualified healthcare professional. Always consult your doctor before making any decisions about testing or care.
